 AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing a pipeline of six gene-therapeutics covering Fabrys disease AVR-RD-01, Gaucher Type 1 AVR-RD-02, Cystinosis AVR-RD-04, Hunter syndrome AVR-RD-05, Gaucher Type 3 AVR-RD-06, and Pompe disease AVR-RD-03, a 4.6B combined-market. 